Home › Forums › Main Forum › Experts Corner › Resistance › Prevalence of Resistance-Associated Substitutions in HCV

Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • 6 July 2016 at 2:35 pm #20574
    Avatar photoLondonGirl
    • Guardian Angel
    • ★★★★★
    @londongirl

    “This paper, which some Drs feel is important, not least for NHS patients in England” :(a leading NHS consultant).

    Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir

    “We evaluated the effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection”.

    http://www.gastrojournal.org/article/S0016-5085(16)34614-5/abstract?referrer=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F27296509

    GT1a Dec14 F2/8.7 VL 900000-2.5M
    Jan16 Hepcivir-L MonkMed/Redemption
    Baseline: VL 913575 Alt 76 Platelets low
    Wk2 VL1157 Alt 23
    DET Wk 8 VL 32 Alt19 ‘In the slow lane’
    June16 Fibro 5.7 F0/1 LIF 1.5
    Wk 11 VL<12 Alt 13 Det/Unq
    Extending tx 12 wks Mylan Sofo/Dac MonkMed
    Wk 14 VL <12 Det/Unq
    Wk 16 VL UNDETECTED
    Wk 22 + 4 Wks Sunprevir FixHepC
    Wk 24 UNDETECTED Alt 13
    Wk 12 post tx SVR12 Wk 26 SVR24
    Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

    6 July 2016 at 2:54 pm #20575
    Avatar photoGT2
    • Guardian Angel
    • ★★★★★
    @gt2

    Good News for GT1s

    Conclusions
    Baseline RASs in NS5A have minimal effects on patients’ response to ledipasvir/sofosbuvir therapy. When these RASs do have effects, they could be largely overcome by extending treatment duration or through treatment intensification.

    :)

    1983: Hospitalised with Acute non-A, non-B Hepatitis after ICU blood transfusion 3mths earlier => HCV GT2
    22/02/16: (pre-tmt) ALT 61, VL 2.48 IU/ml Hepascore 0.32 (F1/2), fatigue, brain fog, bloating (Treatment Naïve)
    10/04/16: (Start tmt) Sofovir +DaclaHep (SOF + DCV) by Hetero Labs in India
    09/05/16: ALT 34, VL: NOT Detected :cheer: 🙂 , FBG 11.9 :huh:
    17/6/16 FBG 5.7; PPBG (@14.22) 6.9 (@ 20.45) 7.1; BP 124/72
    🙂 (Accu-Chek Mobile & Omron Auto BP Monitor) 🙂

    7 July 2016 at 12:18 pm #20639
    Avatar photoLondonGirl
    • Guardian Angel
    • ★★★★★
    @londongirl

    Yes, good news, but good to be aware for the small % – So that those in the ‘slow-lane’ can know there is the option to extend treatment if necessary with generics safely via this website in time; especially if they are being treated by NHS England who are not always prescribing the recommended tx period and generally not offering any treatment extention from what I’ve heard.

    GT1a Dec14 F2/8.7 VL 900000-2.5M
    Jan16 Hepcivir-L MonkMed/Redemption
    Baseline: VL 913575 Alt 76 Platelets low
    Wk2 VL1157 Alt 23
    DET Wk 8 VL 32 Alt19 ‘In the slow lane’
    June16 Fibro 5.7 F0/1 LIF 1.5
    Wk 11 VL<12 Alt 13 Det/Unq
    Extending tx 12 wks Mylan Sofo/Dac MonkMed
    Wk 14 VL <12 Det/Unq
    Wk 16 VL UNDETECTED
    Wk 22 + 4 Wks Sunprevir FixHepC
    Wk 24 UNDETECTED Alt 13
    Wk 12 post tx SVR12 Wk 26 SVR24
    Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

  • Author
    Posts
Viewing 3 posts - 1 through 3 (of 3 total)
  • You must be logged in to reply to this topic.